TP53 and lung carcinoma: Similarly, Bhatt et al. found that the combination of HCQ and trametinib resulted in synergistic anti-proliferative activity in KrasG12D/+;Lkb1−/−(KL) lung cancer cells, but not in KrasG12D/+;p53−/−(KP) lung cancer cells.